XML 78 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisition (Details) (USD $)
 3 Months Ended 5 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2014
Sep. 30, 2013
May 08, 2014
Dec. 31, 2013
Business Acquisition [Line Items]              
Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions $ (2,900,000)            
Change in acquisition-related contingent consideration 1,100,000     1,090,000 0    
Impairment of Intangible Assets (Excluding Goodwill) (1,500,000)            
Goodwill, Period Increase (Decrease) (300,000)            
Revenues 4,117,783 3,706,918   12,662,290 10,590,237    
Net loss (17,176,644) (9,276,601)   (43,776,220) (26,766,572)    
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual     30,000        
Common Stock, Shares, Issued 35,485,523   35,485,523 35,485,523   5,329,593 27,196,537
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High           90,000,000  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net           19,400,000  
Acquisition-related contingent consideration 22,430,000   22,430,000 22,430,000   11,900,000 9,450,000
Business Acquisition, Transaction Costs           33,500,000  
Cash and cash equivalents           51,200  
Accounts receivable, net of allowance for doubtful accounts of $390,118 and $391,829 at March 31, 2014 and December 31, 2013, respectively           45,100  
Prepaid expenses and other current assets           19,200  
Property, plant and equipment, net           1,040,900  
Other assets           201,000  
Goodwill 25,209,336   25,209,336 25,209,336   14,091,700 11,117,770
Equity Issued in Business Combination, Fair Value Disclosure           21,600,000  
Intangible assets, net           34,290,000  
Accounts Payable, Current           (333,100)  
Accrued Liabilities, Current           (2,014,100)  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent           (13,901,200)  
Deferred Tax Liabilities, Net, Noncurrent 600,000     (142,183) (492,325)    
Business Acquisition, Pro Forma Net Income (Loss)     (5,400,000)        
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders $ (0.48) $ (0.45) $ (0.17) $ (1.37) $ (1.43)    
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net           33,490,700  
NeoStem Oncology [Member]
              
Business Acquisition [Line Items]              
Business Acquisition, Pro Forma Revenue   3,893,000   13,373,000 11,175,000    
Business Acquisition, Pro Forma Net Income (Loss)   (10,586,000)   (46,273,000) (30,549,000)    
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual   (10,380,000)   (45,759,000) (30,229,000)    
Business Acquisition, Pro Forma Earnings Per Share, Diluted   $ (0.41)   $ (1.24) $ (1.27)    
NeoStem, Inc. [Member]
              
Business Acquisition [Line Items]              
Revenues   3,707,000   12,662,000 10,590,000    
Net loss   (9,277,000)   (43,776,000) (26,767,000)    
Net Income (Loss) Attributable to Parent   (9,071,000)   (43,262,000) (26,447,000)    
Goodwill $ 25,209.3   $ 25,209.3 $ 25,209.3     $ 11,117.8
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders   $ (0.45)   $ (1.37) $ (1.43)